Kissei Pharmaceutical Co., Ltd.
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 6 name spellings.
6
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Mar 19 to 22, 2027 · next Mar 19
- 1 fee due Apr 27, 2027The maintenance fee for Salt of fused heterocyclic derivative and crystal thereof (US 9,169,266) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
- 2 fees due Sep 1 to 3, 2027 · next Sep 1
- 2 fees due Nov 12 to 14, 2027 · next Nov 12
Recent changes
- 1 term has ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,834,193 | Indoline compound and process for producing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 8,003,647 | (AZA)INDOLE Derivative and Use Thereof for Medical Purposes In force · High confidence | In force | High confidence | |
| US 8,993,616 | (AZA)INDOLE Derivative and Use Thereof for Medical Purposes In force · Low confidence | In force | Low confidence | |
| US 8,399,418 | Monosebacate of pyrazole derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 8,426,427 | Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes In force · From the USPTO record | In force | From the USPTO record | |
| US 9,040,693 | Fused Heterocyclic Derivative, Medicinal Composition Containing the Same, and Medicinal Use Thereof In force · High confidence | In force | High confidence | |
| US 9,737,539 | Salt of fused heterocyclic derivative and crystal thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,016,433 | Salt of fused heterocyclic derivative and crystal thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,576,084 | Salt of fused heterocyclic derivative and crystal thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,169,266 | Salt of fused heterocyclic derivative and crystal thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 24: 5 patents in force now held by others · 92 lapsed for an unpaid fee · 60 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 1 abandoned · 39 no status recorded